HCWB HCW Biologics Inc.

Price Chart

Executive Summary

HCW Biologics entered into a securities purchase agreement to sell 2,846,975 shares of common stock (or pre-funded warrants in lieu) at $1.28/share, plus 2,846,975 common warrants exercisable at $1.28 for 5.5 years, in a private placement raising approximately $3.6M in gross proceeds. The company also entered into a registration rights agreement to register the resale of the shares and warrants, and a placement agency agreement with E.F. Hutton & Co. paying 8% cash fee and 0.5% non-accountable expense allowance. Directors, executive officers, and 5%+ holders signed 6-month lock-up agreements, and the company agreed to a 60-day standstill on further equity issuances (with an exception for its existing ELOC with Square Gate Capital starting June 15, 2026). The offering is dilutive (~18% of current shares outstanding based on $16M market cap and $1.28 price) and signals urgent capital needs for a micro-cap biotech with no disclosed revenue.

Key Financial Metrics

Actionable Insight

Key Facts

• Company sold 2,846,975 shares (or pre-funded warrants) at $1.28/share, raising ~$3.6M in gross proceeds.
• Purchasers also received 2,846,975 common warrants exercisable at $1.28 for 5.5 years (100% warrant coverage).
• Directors, executive officers, and 5%+ holders signed 6-month lock-up agreements.
• Company agreed to 60-day standstill on further equity issuances (except existing ELOC with Square Gate Capital starting June 15, 2026).
• Registration rights agreement requires filing resale registration statement within 15 days and effectiveness within 60 days.
• Placement agent E.F. Hutton receives 8% cash fee and 0.5% non-accountable expense allowance.
• Company may use up to $620,000 and $507,000 to settle debt and litigation with Eirgenix, Inc. and B&I Contractors, Inc.
• Market cap is ~$16M; offering represents significant dilution (~18% of pre-offering shares outstanding).

Financial Impact

~$3.6M gross proceeds raised at $1.28/share, representing ~18% dilution based on $16M market cap. Net proceeds after fees (~8.5% total) ~$3.3M.

Risk Factors

• Significant dilution from the offering and potential future exercise of warrants.
• Pre-revenue biotech with no disclosed product revenue; cash burn may require further financing.
• Existing ELOC with Square Gate Capital could add further dilution starting June 15, 2026.
• Registration of resale shares could lead to immediate selling pressure once effective.
• Use of proceeds for debt/litigation settlement indicates financial constraints.

Market Snapshot

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

US Market Status